David Loury

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text

Life Sciences, Immunology, Pharmacology +17

Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity

D. A. Steinberg, Malinda A. Hurst, Craig A. Fujii et al. · Antimicrobial Agents and Chemotherapy · 1997 · 388 citations

Life Sciences, Microbiology, Antimicrobial Resistance +13

Functional role of M₂ and M₃ muscarinic receptors in the urinary bladder of rats <i>in vitro</i> and <i>in vivo</i>

Sharath S. Hegde, Agnès Choppin, D BONHAUS et al. · British Journal of Pharmacology · 1997 · 306 citations · Full text

Medicine, Pharmacology, Molecular Pharmacology +12

The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT₃ receptors, <i>in vitro</i>

Erik H.F. Wong, Robin D. Clark, Edward Leung et al. · British Journal of Pharmacology · 1995 · 170 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues

Jie Chen, Timothy J. Falla, Hongjian Liu et al. · Biopolymers · 2000 · 164 citations

Pharmacy, Biochemistry, Pharmacology +14